# RT Plus EGFR-TKI for Wild-type NSCLC

> **NCT02738983** · PHASE2 · UNKNOWN · sponsor: **Hangzhou Cancer Hospital** · enrollment: 22 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)

## Interventions

- **DRUG:** Erlotinib (trade name: Tarceva®) or Icotinib (trade name: Conmana®)
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT02738983
- **Lead sponsor:** Hangzhou Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-01
- **Primary completion:** 2016-12
- **Final completion:** 2017-12
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2016-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02738983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02738983, "RT Plus EGFR-TKI for Wild-type NSCLC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02738983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*